Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites
Article first published online: 17 JAN 2014
© 2014, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 54, Issue 6, pages 696–706, June 2014
How to Cite
Ouellet, D., Gibiansky, E., Leonowens, C., O'Hagan, A., Haney, P., Switzky, J. and Goodman, V. L. (2014), Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. Journal of Clinical Pharma, 54: 696–706. doi: 10.1002/jcph.263
- Issue published online: 3 MAY 2014
- Article first published online: 17 JAN 2014
- Accepted manuscript online: 9 JAN 2014 08:02AM EST
- Manuscript Accepted: 4 JAN 2014
- Manuscript Received: 15 OCT 2013
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Figure S1. Relationship between dabrafenib, hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib trough concentrations.
Figure S2. Goodness of fit for final PK model.
Figure S3. Prediction-corrected visual predictive check for final PK model.
Figure S4. Effects of covariates on trough concentrations for dabrafenib, hydroxy-, carboxy, and desmethyl-dabrafenib from the full models.
Table S1. Summary of the Clinical Studies Included in the Population Pharmacokinetic Analysis
Table S2. Covariates Evaluated in the Full Model for Each Pharmacokinetic Parameter
Table S3. Subject Demographics
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.